Clinical Trial: Phase 1 Study of GL0034 Pharmacokinetics in Participants With Moderate and Severe Renal Impairment and With Normal Renal Function

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07385547) titled 'Phase 1 Study of GL0034 Pharmacokinetics in Participants With Moderate and Severe Renal Impairment and With Normal Renal Function' on Jan. 27.

Brief Summary: This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist. Approximately 40 adult participants will be enrolled across four groups: normal renal function, moderate renal impairment, severe renal impairment without dialysis, and severe renal impairment with dialysis. Each participant will receive a single subcutaneous dose of GL0034. Blood samples will...